gracecast-118_lung-cancer_asco 2012 lung cancer highlights: question and answer session
Published 11 years ago • 126 plays • Length 20:34Download video MP4
Download video MP3
Similar videos
-
23:32
gracecast-077_lung-cancer_asco 2011 highlights - advanced/metastatic nsclc
-
4:30
gracecast-117_lung-cancer_asco 2012 lc highlights: dr. neal on molecular targets in squamous nsclc
-
13:40
gracecast-104_lung-cancer_immunotherapy for lung cancer: q and a session
-
7:44
asco lung cancer highlights, part 1: introduction to stage iii nsclc
-
1:59:57
grace - global resource for advancing cancer education live stream
-
6:00
perioperative keytruda for early stage nsclc-leading developments & current questions in lung cancer
-
5:11
gracecast-114_lung-cancer_asco 2012 lc highlights: dr. neal on mek inhibitor selumetinib in nsclc
-
4:42
grace targeted therapies in lung cancer 2021 - anxiety burden: wait for results, beginning treatment
-
7:41
gracecast-113_lung-cancer_asco 2012 lc highlights: dr. neal on anti-pd-1 immunotherapy for nsclc
-
35:31
gracecast-078_lung-cancer_asco 2011 highlights - q&a with pinder-schenk & hanna
-
11:13
gracecast-091_lung-cancer_highlights 2011: the egfr axis
-
5:11
gracecastuc-015_lung_what is the biology of a mixed response in lung cancer?
-
1:44
extended interval dosing for pembrolizumab - lung cancer onctalk 2022
-
5:09
gracecastuc-013_lung_what should we do for a "mixed response" to lung cancer treatment?
-
18:51
gracecast-140_lung_highlights in lung cancer, 2012: new options for egfr mutation-positive nsclc
-
7:55
gracecast-083_lung-cancer_q&a with dr. lilenbaum on managing lung cancer in elderly patients
-
7:54
keytruda combined with anti-vegf treatment:use in patients with advanced nsclc-asco lung review 2022
-
5:27
gracecast-144_lung_highlights in lung cancer, 2013: mek inhibitors for kras mutation-positive nsclc
-
14:35
gracecast-027_lung-cancer_the role of surgery in nsclc management